Stimulating immune responses to fight cancer: Basic biology and mechanisms

Asia-Pacific Journal of Clinical Oncology

Volumn 11, Issue , 2015, Pages 9-15

  O’Byrne, Kenneth ^a,b,c  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

bioactive lipids; cancer; cytokines; hypoxia; immune response; immunotherapy

Indexed keywords

CANCER VACCINE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ANTAGONISTS AND INHIBITORS; CELLULAR IMMUNITY; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; TREATMENT OUTCOME;

ANTIGENS, CD274; CANCER VACCINES; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; LUNG NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; TREATMENT OUTCOME;

EID: 84991539367     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/AJCO.12410     Document Type: Review

References (58)

1. Yaglom JA, McFarland C, Mirny L, Sherman MY. Oncogene-triggered suppression of DNA repair leads to DNA instability in cancer. Oncotarget 2014; 5: 8367–78.
2. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008; 319: 1352–5.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–74.
4. Brighenti E, Calabrese C, Liguori G et al. Interleukin 6 downregulates p53 expression and activity by stimulating ribosome biogenesis: a new pathway connecting inflammation to cancer. Oncogene 2014; 33: 4396–406.
5. Ling S, Feng T, Jia K, Tian Y, Li Y. Inflammation to cancer: the molecular biology in the pancreas (Review). Oncol Lett 2014; 7: 1747–54.
6. O’Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001; 85: 473–83.
7. Cathcart MC, Gately K, Cummins R et al. Thromboxane synthase expression and correlation with VEGF and angio-genesis in non-small cell lung cancer. Biochim Biophys Acta 2014; 1842: 747–55.
8. Larkins TL, Nowell M, Singh S, Sanford GL. Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer 2006; 6: 181.
9. Pidgeon GP, Lysaght J, Krishnamoorthy S et al. Lipoxy-genase metabolism: roles in tumor progression and sur-vival. Cancer Metastasis Rev 2007; 26: 503–24.
10. Zarghi A, Arfaei S, Selective COX. 2 inhibitors: a review of their structure-activity relationships. Iran J Pharm Res 2011; 10: 655–83.
11. Li F, Liu Y, Chen H et al. EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features. J Exp Clin Cancer Res 2011; 30: 27.
12. Castelao JE, Bart RD 3rd, DiPerna CA, Sievers EM, Bremner RM. Lung cancer and cyclooxygenase-2. Ann Thorac Surg 2003; 76: 1327–35.
13. Hida T, Yatabe Y, Achiwa H et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 58: 3761–4.
14. Edelman MJ, Hodgson L, Wang X, Kratzke RA, Vokes EE. Cyclooxygenase-2 (COX-2) as a predictive marker for the use of COX-2 inhibitors in advanced non-small-cell lung cancer. J Clin Oncol 2012; 30: 2019–20.
15. Edelman MJ, Tan MT, Fidler MJ et al. Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer. J Clin Oncol 2015; 33: 189–94.
16. Richardson CM, Richardson D, Swinson DE, Swain WA, Cox G, O’Byrne KJ. Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancer. Lung Cancer 2005; 48: 47–57.
17. Richardson CM, Sharma RA, Cox G, O’Byrne KJ. Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy. Lung Cancer 2003; 39: 1–13.
18. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7: 211–17.
19. Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature 2004; 431: 405–6.
20. Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol 2012; 22: 33–40.
21. Dalgleish AG, O’Byrne K. Inflammation and cancer: the role of the immune response and angiogenesis. Cancer Treat Res 2006; 130: 1–38.
22. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436–44.
23. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009; 9: 361–71.
24. Sethi G, Sung B, Aggarwal BB. TNF: a master switch for inflammation to cancer. Front Biosci 2008; 13: 5094– 107.
25. Wu Y, Zhou BP. TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer 2010; 102: 639–44.
26. Apte RN, Dotan S, Elkabets M et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 2006; 25: 387–408.
27. Dinarello CA. The paradox of pro-inflammatory cytokines in cancer. Cancer Metastasis Rev 2006; 25: 307–13.
28. Lewis AM, Varghese S, Xu H, Alexander HR. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med 2006; 4: 48.
29. Apte RN, Voronov E. Is interleukin-1 a good or bad “guy” in tumor immunobiology and immunotherapy? Immunol Rev 2008; 222: 222–41.
30. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26: 225–39.
31. Glazer PM, Hegan DC, Lu Y, Czochor J, Scanlon SE. Hypoxia and DNA repair. Yale J Biol Med 2013; 86: 443–51.
32. Jackson AL, Zhou B, Kim WY. HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer. Expert Opin Ther Targets 2010; 14: 1047–57.
33. Le QT, Shi G, Cao H et al. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 2005; 23: 8932–41.
34. Baird A-M, Gray S, O’Byrne K. Chronic exposure to TNF-α and IL-1β increases the invasive potential of a human bronchial epithelial cell line. Lung Cancer 2012; 75: S1.
35. Baird A-M, Gray S, O’Byrne K. A model of chronic inflammation affects the invasive capacity and induces several hallmarks of cancer in a normal bronchial epithelial cell line. J Thorac Oncol 2013; 8: S741.
36. Baird A-M, Gray S, Richard D, O’Byrne K. Sustained exposure to TNF-α and IL-1β increases the invasion, adhesion and proliferative potential of a normal bronchial epithelial cell line. Asia-Pacific J Clin Oncol 2014; 10(Suppl. 8): 156.
37. Ramirez RD, Sheridan S, Girard L et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 2004; 64: 9027–34.
38. Rahim MM, Tu MM, Mahmoud AB et al. Ly49 receptors: innate and adaptive immune paradigms. Front Immunol 2014; 5: 145.
39. Tarhini A, Lo E, Minor DR. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm 2010; 25: 601–13.
40. Massari F, Santoni M, Ciccarese C et al. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. Cancer Treat Rev 2015; 41: 114–21.
41. Winter H, van den Engel NK, Rusan M et al. Active-specific immunotherapy for non-small cell lung cancer. J Thorac Dis 2011; 3: 105–14.
42. Dieu-Nosjean MC, Antoine M, Danel C et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26: 4410–17.
43. Hiraoka K, Miyamoto M, Cho Y et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006; 94: 275–80.
44. O’Callaghan D, Rexhepaj E, Gately K et al. Effect of pattern of lymphocyte infiltration in NSCLC on outcome. J Clin Oncol 2009; 27: 15s.
45. Kawai O, Ishii G, Kubota K et al. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 2008; 113: 1387–95.
46. Welsh TJ, Green RH, Richardson D, Waller DA, O’Byrne KJ, Bradding P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 2005; 23: 8959– 67.
47. Al-Shibli K, Al-Saad S, Donnem T, Persson M, Bremnes RM, Busund LT. The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology 2009; 55: 301–12.
48. McCoy MJ, Nowak AK, van der Most RG, Dick IM, Lake RA. Peripheral CD8(+) T cell proliferation is prognostic for patients with advanced thoracic malignancies. Cancer Immunol Immunother 2013; 62: 529–39.
49. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 2007; 121: 1–14.
50. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006; 90: 51–81.
51. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29: 235–71.
52. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006; 90: 297–339.
53. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252– 64.
54. Luke JJ, Ott P. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotar-get 2015; 6(8): 3479–92.
55. Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic mela-noma. N Engl J Med 2010; 363: 711–23.
56. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677–704.
57. Sansom DM. CD28, CTLA-4 and their ligands: who does what and to whom? Immunology 2000; 101: 169–77.
58. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol 1999; 162: 5813–20.